Przemysława Jarosz‐Chobot

ORCID: 0000-0002-1120-0994
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Diabetes and associated disorders
  • Diabetes Management and Research
  • Pancreatic function and diabetes
  • Metabolism, Diabetes, and Cancer
  • Nutrition and Health Studies
  • Diabetes Treatment and Management
  • Hyperglycemia and glycemic control in critically ill and hospitalized patients
  • Diet, Metabolism, and Disease
  • Diet and metabolism studies
  • Childhood Cancer Survivors' Quality of Life
  • Digestive system and related health
  • Adolescent and Pediatric Healthcare
  • Growth Hormone and Insulin-like Growth Factors
  • Immunodeficiency and Autoimmune Disorders
  • Obesity and Health Practices
  • Celiac Disease Research and Management
  • Immune Cell Function and Interaction
  • Thyroid Disorders and Treatments
  • Adipose Tissue and Metabolism
  • Genetics and Neurodevelopmental Disorders
  • Lipoproteins and Cardiovascular Health
  • Child and Adolescent Health
  • Food Security and Health in Diverse Populations
  • Blood Pressure and Hypertension Studies
  • COVID-19 Clinical Research Studies

Medical University of Silesia
2016-2025

John Paul II Hospital
2022-2024

Górnośląskie Centrum Zdrowia Dziecka w Katowicach
2022-2024

University of Helsinki
2013-2022

Helsinki University Hospital
2022

University of Silesia in Katowice
2014-2021

Górnośląskie Centrum Medyczne
1998-2020

ZRE Gdańsk (Poland)
2020

Gdańsk Medical University
2013-2018

Medical University of Lodz
2018

Against a background of near-universally increasing incidence childhood type 1 diabetes, recent reports from some countries suggest slowing in this increase. Occasional also describe cyclical variations incidence, with periodicities between 4 and 6 years.Age/sex-standardised rates for the 0- to 14-year-old age group are reported 26 European centres (representing 22 countries) that have registered newly diagnosed individuals geographically defined regions up 25 years during period 1989-2013....

10.1007/s00125-018-4763-3 article EN cc-by Diabetologia 2018-11-23

The aim of this study was to dynamic changes in the prevalence different types diabetes paediatric populations Poland, with a specific focus on monogenic (MD). Using epidemiologic data (PolPeDiab Collaboration) and nationwide genetic test results (TEAM Programme), we compared type 1, 2 cystic fibrosis-related (CFRD) MD. Genetically confirmed MD included MODY, neonatal Wolfram Alström syndromes. covered all children aged 0–18 years treated for between 2005 2011 three regions, inhabited by...

10.1007/s00125-012-2621-2 article EN cc-by-nc Diabetologia 2012-07-10

The 2019 Diabetes Poland guidelines -summary of the most important changes Since 2005, (PTD, Polskie Towarzystwo Diabetologiczne) prepares and publishes annually its on management diabetic patients.The idea guideline development was first suggested in 2004 by Prof. Jacek Sieradzki who president PTD at that time.The chairperson Guideline Writing Group Władysław Grzeszczak acted this capacity 2005-2011, followed next PTD, 2011-2015, Leszek Czupryniak.The are a product team nearly 50 experts...

10.5603/dk.2019.0001 article EN cc-by-nc-nd Clinical Diabetology 2019-01-08

Sensor-augmented pump (SAP) therapy can improve glycemic control, compared with multiple daily insulin injections or alone, without increasing the risk of hypoglycemia.

10.1089/dia.2012.0288 article EN Diabetes Technology & Therapeutics 2013-02-25

Recent studies suggest that immunotherapy using T regulatory cells (Tregs) prolongs remission in type 1 diabetes (T1DM). Here, we report factors possibly affect the efficacy of this treatment.The metabolic and immune background 12 children with recently diagnosed T1DM, as well untreated subjects, during a 2-year follow-up is presented. Patients were treated up to 30 × 106/kg b.w. autologous expanded CD3+CD4+CD25highCD127- Tregs.The disease progressed all patients insulin-dependent 2 years...

10.1186/s12967-016-1090-7 article EN cc-by Journal of Translational Medicine 2016-12-01

E. Cengiz is a scientific advisor for Eli Lilly, Novo Nordisk, Adocia and Arecor. TD has received speaker's honoraria research support from or consulted Astra Zeneca, Bayer, Boehringer, Dexcom, Lifescan, Medtronic, Provention Bio, Roche, Sanofi, Ypsomed shareholder of Drea Med Ltd. TA, JF, DB, SH, MP, Codner have no disclosures.

10.1111/pedi.13442 article EN Pediatric Diabetes 2022-12-01

The International Society for Pediatric and Adolescent Diabetes (ISPAD) guidelines represent a rich repository that serves as the only comprehensive set of clinical recommendations children, adolescents, young adults living with diabetes worldwide. This chapter builds on 2022 ISPAD guidelines, updates principles intensive insulin regimens, including more forms multiple daily injections new-generation faster-acting ultra-long-acting insulins; summary adjunctive medications used alongside...

10.1159/000543169 article EN Hormone Research in Paediatrics 2025-01-30

We analysed the temporal changes in incidence of childhood type 1 diabetes and its demographic determinants Poland from 1989 to 2004, validating model with data 1970 1989. also estimated a predictive trends for near future. Children under 15 years newly diagnosed mellitus drawn seven regional registries were ascertained prospectively using Epidemiology Prevention Diabetes study (EURODIAB) criteria. The rates (IRs) dependency age, sex, seasonality, geographical region population density. Time...

10.1007/s00125-010-1993-4 article EN cc-by-nc Diabetologia 2010-12-16

OBJECTIVE The aim if the study was to investigate whether children born older mothers have an increased risk of type 1 diabetes by performing a pooled analysis previous studies using individual patient data adjust for recognized confounders. RESEARCH DESIGN AND METHODS Relevant published before June 2009 were identified from MEDLINE, Web Science, and EMBASE. Authors contacted asked provide or conduct prespecified analyses. Risk estimates maternal age calculated each study, after adjustment...

10.2337/db09-1166 article EN cc-by-nc-nd Diabetes 2009-10-29

To present the incidence trend for Type 1 diabetes in Polish children aged 0-14 years, updated using data collected during 2005-2012, and assess reliability of predictive model constructed previously 1989-2004 database.Children < 15 years with newly diagnosed are recorded prospectively (EURODIAB criteria) several regional registers Poland. Age- gender-standardized rates were calculated per 100 000 persons/year. Incidence analysed terms dependency on age, gender, geographical region...

10.1111/dme.13345 article EN Diabetic Medicine 2017-03-03

2022 Guidelines on the management of patients with diabetes A position Diabetes Poland Rules for diagnosing carbohydrate metabolism disordersKey recommendations• Blood sugar tests early detection prediabetes/type 2 should be performed people over 45, as well younger overweight or obese if there is at least one additional risk factor diabetes.[B]• Women not previously diagnosed undergo an oral glucose tolerance test between 24 th and 28 week pregnancy to diagnose gestational diabetes.[A]•...

10.5114/ctd/146259 article EN Current Topics in Diabetes 2022-01-30

Background and aims MiniMed 780G is the first Advanced Hybrid Closed Loop (AHCL) system in Poland, approved EU 2020. To date, observations of glycemic control up to 12 months have been published. This study aimed analyze anthropometric parameters children adolescents with type 1 diabetes (T1D) after two years using AHCL system. Materials methods We prospectively collected data, pump, continuous glucose records fifty T1D (9.9 ± 2.4 years, 24 (48%) boys, for 3.9 2.56 years) an compared...

10.3389/fendo.2024.1332418 article EN cc-by Frontiers in Endocrinology 2024-02-08

Introduction The identification of type 1 diabetes at an early presymptomatic stage has clinical benefits. These include a reduced risk diabetic ketoacidosis (DKA) the manifestation disease and significant reduction in symptoms. European action for Diagnosis Early Non-clinical Type For Interception (EDENT1FI) represents pioneering effort to advance detection through public health screening. With EDENT1FI Master Protocol, project aims harmonise standardise screening early-stage care. Methods...

10.1136/bmjopen-2024-088522 article EN cc-by-nc-nd BMJ Open 2025-01-01
Coming Soon ...